Abstract On March 11, 2020, the World Health Organization declared Coronavirus Disease
2019 (COVID-19) a pandemic. Till now, it affected 452.4 million (Spain, 11.18 million) …

Background A significant increased risk of complications and mortality in
immunocompromised patients affected by COVID-19 has been described. However, the …

Background The presence of co-morbidities, including underlying respiratory problems, has
been identified as a risk factor for severe COVID-19 disease. Information on the clinical …

Background Viral infections can cause significant morbidity in cystic fibrosis (CF). The
current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could …

An excessive, non‐resolving inflammatory response underlies severe COVID‐19 that may
have fatal outcomes. Therefore, the investigation of endogenous pathways leading to …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and
the development of life-threatening COVID-19 are believed to disproportionately affect …

Several risk factors for Coronavirus-2019 (COVID-19) disease have been highlighted in
clinical evidence. Among the various risk factors are advanced age, metabolic illness such …

Purpose To describe the clinical course of COVID-19 in patients with cystic fibrosis (CF) and
to identify risk factors for severe COVID-19. Methods We conducted a prospective study …

People with cystic fibrosis should be considered at increased risk of developing severe
symptoms of COVID-19. Strikingly, a broad array of evidence shows reduced spread of …

Background This international study aimed to characterise the impact of acute SARS-CoV-2
infection in people with cystic fibrosis and investigate factors associated with severe …